[{"id":"fa153fa1-88be-494d-a000-63ab41769eb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00454194","created_at":"2021-01-18T01:36:36.230Z","updated_at":"2024-07-02T16:37:24.233Z","phase":"Phase 2","brief_title":"Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00454194","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" FLT1","pipe":"","alterations":" ","tags":["FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 09/01/2007","start_date":" 09/01/2007","primary_txt":" Primary completion: 07/01/2010","primary_completion_date":" 07/01/2010","study_txt":" Completion: 05/01/2013","study_completion_date":" 05/01/2013","last_update_posted":"2017-03-21"}]